Literature DB >> 8730729

Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes.

C Zocchi1, E Ongini, S Ferrara, P G Baraldi, S Dionisotti.   

Abstract

1. The present study describes the binding to rat striatal A2A adenosine receptors of the new potent and selective antagonist radioligand, [3H]-5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazol o [1,5-c] pyrimidine, [3H]-SCH 58261. 2. [3H]-SCH 58261 specific binding to rat striatal membranes ( > 90%) was saturable, reversible and dependent upon protein concentration. Saturation experiments revealed that [3H]-SCH 58261 labelled a single class of recognition sites with high affinity (Kd = 0.70 nM) and limited capacity (apparent Bmax = 971 fmol mg-1 of protein). The presence of 100 microM GTP in the incubation mixture did not modify [3H]-SCH 58261 binding parameters. 3. Competition experiments showed that [3H]-SCH 58261 binding is consistent with the labelling of A2A striatal receptors. Adenosine receptor agonists competed with the binding of 0.2 nM [3H]-SCH 58261 with the following order of potency: 2-hexynyl-5'-N-ethyl carboxamidoadenosine (2HE-NECA) > 5'-N-ethylcarboxamidoadenosine (NECA) > 2-[4-(2-carboxyethyl)-phenethylamino]-5'-N-ethylcarboxamidoadenosi ne (CGS 21680) > 2-phenylaminoadenosine (CV 1808) > R-N6-phenylisopropyladenosine (R-PIA) > N6-cyclohexyladenosine (CHA) = 2-chloro-N6-cyclopentyladenosine (CCPA) > S-N6-phenylisopropyladenosine (S-PIA). 4. Adenosine antagonists inhibited [3H]-SCH 58261 binding with the following order: 5-amino-9-chloro-2-(2-furyl)-[1,2,4]-triazolo[1,5-c] quinazoline (CGS 15943) > 5-amino-8-(4-fluorobenzyl)-2-(2-furyl)-pyrazolo [4,3-e]-1,2,4-triazolo [1,5-c] pyrimidine (8FB-PTP) = SCH 58261 > xanthine amine congener (XAC) = (E,18%-Z,82%)7-methyl-8-(3,4-dimethoxystyryl)-1,3-dipropylxanthine (KF 17837S) > 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) > or = 8-phenyltheophylline (8-PT). 5. The Ki values for adenosine antagonists were similar to those labelled with the A2A agonist [3H]-CGS 21680. Affinities of agonists were generally lower. The A1-selective agonist, R-PIA, was found to be about 9 fold more potent than its stereoisomer, S-PIA, thus showing the stereoselectivity of [3H]-SCH 58261 binding. Except for 8-PT, the adenosine agonists and antagonists examined inhibited [3H]-SCH 58261 binding with Hill coefficients not significantly different from unity. 6. The present results indicate that [3H]-SCH 58261 is the first non-xanthine adenosine antagonist radioligand which directly labels A2A striatal receptors. High receptor affinity, good selectivity and very low non-specific binding make [3H]-SCH 58261 an excellent probe for studying the A2A adenosine receptor subtype in mammalian brain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730729      PMCID: PMC1909468          DOI: 10.1111/j.1476-5381.1996.tb15296.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells.

Authors:  D van Calker; M Müller; B Hamprecht
Journal:  J Neurochem       Date:  1979-11       Impact factor: 5.372

Review 2.  G proteins: transducers of receptor-generated signals.

Authors:  A G Gilman
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

3.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

4.  Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes.

Authors:  R F Bruns; G H Lu; T A Pugsley
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

5.  Characterization of two affinity states of adenosine A2a receptors with a new radioligand, 2-[2-(4-amino-3-[125I]iodophenyl)ethylamino]adenosine.

Authors:  D R Luthin; R A Olsson; R D Thompson; D R Sawmiller; J Linden
Journal:  Mol Pharmacol       Date:  1995-02       Impact factor: 4.436

6.  [3H]5'-N-ethylcarboxamide adenosine binds to both Ra and Ri adenosine receptors in rat striatum.

Authors:  S M Yeung; R D Green
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-03       Impact factor: 3.000

7.  A new high affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity crosslinking probe.

Authors:  G L Stiles; K A Jacobson
Journal:  Mol Pharmacol       Date:  1987-08       Impact factor: 4.436

8.  Reciprocal modulation of agonist and antagonist binding to A1 adenosine receptors by guanine nucleotides is mediated via a pertussis toxin-sensitive G protein.

Authors:  V Ramkumar; G L Stiles
Journal:  J Pharmacol Exp Ther       Date:  1988-09       Impact factor: 4.030

9.  Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel, non-xanthine adenosine antagonist.

Authors:  M Williams; J Francis; G Ghai; A Braunwalder; S Psychoyos; G A Stone; W D Cash
Journal:  J Pharmacol Exp Ther       Date:  1987-05       Impact factor: 4.030

10.  PD 115,199: an antagonist ligand for adenosine A2 receptors.

Authors:  R F Bruns; J H Fergus; E W Badger; J A Bristol; L A Santay; S J Hays
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-01       Impact factor: 3.000

View more
  10 in total

Review 1.  A(2A) adenosine receptors in human peripheral blood cells.

Authors:  S Gessi; K Varani; S Merighi; E Ongini; P A Borea
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

2.  Functional efficacy of adenosine A₂A receptor agonists is positively correlated to their receptor residence time.

Authors:  Dong Guo; Thea Mulder-Krieger; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

3.  Adenosine A₂A and A₂B receptors are both required for adenosine A₁ receptor-mediated cardioprotection.

Authors:  Enbo Zhan; Victoria J McIntosh; Robert D Lasley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-08       Impact factor: 4.733

4.  BDNF-induced presynaptic facilitation of GABAergic transmission in the hippocampus of young adults is dependent of TrkB and adenosine A2A receptors.

Authors:  Mariana Colino-Oliveira; Diogo M Rombo; Raquel B Dias; Joaquim A Ribeiro; Ana M Sebastião
Journal:  Purinergic Signal       Date:  2016-02-20       Impact factor: 3.765

5.  Interactive role of adenosine and dopamine in the opiate withdrawal syndrome.

Authors:  Luigi Stella; Vito De Novellis; Maria Redenta Vitelli; Annalisa Capuano; Filomena Mazzeo; Liberato Berrino; Francesco Rossi; Amelia Filippelli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-07-17       Impact factor: 3.000

6.  The adenosine A2A receptor antagonist ZM241385 enhances neuronal survival after oxygen-glucose deprivation in rat CA1 hippocampal slices.

Authors:  A M Pugliese; C Traini; S Cipriani; M Gianfriddo; T Mello; M G Giovannini; A Galli; F Pedata
Journal:  Br J Pharmacol       Date:  2009-05-05       Impact factor: 8.739

7.  Binding of the prototypical adenosine A(2A) receptor agonist CGS 21680 to the cerebral cortex of adenosine A(1) and A(2A) receptor knockout mice.

Authors:  Luísa V Lopes; Linda Halldner; Nelson Rebola; Björn Johansson; Catherine Ledent; Jian Fan Chen; Bertil B Fredholm; Rodrigo A Cunha
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

8.  Selective adenosine A2A receptor agonists and antagonists protect against spinal cord injury through peripheral and central effects.

Authors:  Irene Paterniti; Alessia Melani; Sara Cipriani; Francesca Corti; Tommaso Mello; Emanuela Mazzon; Emanuela Esposito; Placido Bramanti; Salvatore Cuzzocrea; Felicita Pedata
Journal:  J Neuroinflammation       Date:  2011-04-12       Impact factor: 8.322

9.  Effects of intra-accumbal or intra-prefrontal cortex microinjections of adenosine 2A receptor ligands on responses to cocaine reward and seeking in rats.

Authors:  K Wydra; A Suder; M Frankowska; D O Borroto Escuela; K Fuxe; M Filip
Journal:  Psychopharmacology (Berl)       Date:  2018-11-13       Impact factor: 4.530

Review 10.  Adenosine-A2A Receptor Pathway in Cancer Immunotherapy.

Authors:  Changfa Sun; Bochu Wang; Shilei Hao
Journal:  Front Immunol       Date:  2022-03-21       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.